Oroxylin A, but Not Vasopressin, Ameliorates Cardiac Dysfunction of Endotoxemic Rats

الملخص EN

The mortality in septic patients with myocardial dysfunction is higher than those without it.

Beneficial effects of flavonoid oroxylin A (Oro-A) on endotoxemic hearts were evaluated and compared with that of arginine vasopressin (AVP) which is used to reverse hypotension in septic patients.

Endotoxemia in rats was induced by one-injection of lipopolysaccharides (LPS, 10 mg/kg, i.p.), and hearts were isolated 5-hrs or 16-hrs later.

Isolated hearts with constant-pressure or constant-flow mode were examined by Langendorff technique.

Rate and force of contractions of isolated atrial and ventricular strips were examined by tissue myography.

Isolated endotoxemic hearts were characterized by decreased or increased coronary flow (CF) in LPS-treated-for-5hr and LPS-treated-for-16-hr groups, respectively, with decreased inotropy in both groups.

Oro-A-perfusion ameliorated while AVP-perfusion worsened the decreased CF and inotropy in both preparations.

Oro-A and AVP, however, did not affect diminished force or rate of contraction of atrial and ventricular strips of endotoxemic hearts.

Oro-A-induced CF increase was not affected following coronary endothelium-denudation with saponin.

These results suggest that Oro-A ameliorates LPS-depressed cardiac functions by increasing CF, leading to positive inotropy.

In contrast, AVP aggravates cardiac dysfunction by decreasing CF.

Oro-A is a potentially useful candidate for treating endotoxemia complicated with myocardial dysfunction.